Doxorubicin Loaded Thermosensitive Magneto-Liposomes Obtained by a Gel Hydration Technique: Characterization and In Vitro Magneto-Chemotherapeutic Effect Assessment
Overview
Authors
Affiliations
The combination of magnetic hyperthermia with chemotherapy is considered a promising strategy in cancer therapy due to the synergy between the high temperatures and the chemotherapeutic effects, which can be further developed for targeted and remote-controlled drug release. In this paper we report a simple, rapid, and reproducible method for the preparation of thermosensitive magnetoliposomes (TsMLs) loaded with doxorubicin (DOX), consisting of a lipidic gel formation from a previously obtained water-in-oil microemulsion with fine aqueous droplets containing magnetic nanoparticles (MNPs) dispersed in an organic solution of thermosensitive lipids (transition temperature of ~43 °C), followed by the gel hydration with an aqueous solution of DOX. The obtained thermosensitive magnetoliposomes (TsMLs) were around 300 nm in diameter and exhibited 40% DOX incorporation efficiency. The most suitable MNPs to incorporate into the liposomal aqueous lumen were Zn ferrites, with a very low coercive field at 300 K (7 kA/m) close to the superparamagnetic regime, exhibiting a maximum absorption rate (SAR) of 1130 W/gFe when dispersed in water and 635 W/gFe when confined inside TsMLs. No toxicity of Zn ferrite MNPs or of TsMLs was noticed against the A459 cancer cell line after 48 h incubation over the tested concentration range. The passive release of DOX from the TsMLs after 48h incubation induced a toxicity starting with a dosage level of 62.5 ug/cm. Below this threshold, the subsequent exposure to an alternating magnetic field (20-30 kA/m, 355 kHz) for 30 min drastically reduced the viability of the A459 cells due to the release of incorporated DOX. Our results strongly suggest that TsMLs represent a viable strategy for anticancer therapies using the magnetic field-controlled release of DOX.
Magnetic Nanoparticles and Drug Delivery Systems for Anti-Cancer Applications: A Review.
Graham W, Torbett-Dougherty M, Islam A, Soleimani S, Bruce-Tagoe T, Johnson J Nanomaterials (Basel). 2025; 15(4).
PMID: 39997849 PMC: 11858650. DOI: 10.3390/nano15040285.
Advances in smart delivery of magnetic field-targeted drugs in cardiovascular diseases.
Wang X, Bai R Drug Deliv. 2023; 30(1):2256495.
PMID: 37702067 PMC: 10501169. DOI: 10.1080/10717544.2023.2256495.
Hybrid Magnetic Lipid-Based Nanoparticles for Cancer Therapy.
Luiz M, Dutra J, Viegas J, de Araujo J, Junior A, Chorilli M Pharmaceutics. 2023; 15(3).
PMID: 36986612 PMC: 10058222. DOI: 10.3390/pharmaceutics15030751.
Khabibullin V, Chetyrkina M, Obydennyy S, Maksimov S, Stepanov G, Shtykov S Int J Mol Sci. 2023; 24(5).
PMID: 36901910 PMC: 10002596. DOI: 10.3390/ijms24054480.
Zhao X, Liu C, Wang Z, Zhao Y, Chen X, Tao H Pharmaceutics. 2023; 15(1).
PMID: 36678904 PMC: 9866545. DOI: 10.3390/pharmaceutics15010276.